Powered by

-Verona Pharma Reports Positive Phase 2 Results with Dry Powder Inhaler Formulation of Ensifentrine in COPD

Aug 06, 2019 - ENP Newswire
Financial Results

LONDON - Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) ('Verona Pharma'), a biopharmaceutical company focused on respiratory diseases, announces positive Phase 2 data with a dry powder inhaler ('DPI') formulation of its lead development product, ensifentrine, for the maintenance treatment of chronic obstructive pulmonary disease ('COPD').

All of the primary and secondary lung function endpoints were met in the Phase 2 trial.

Primary endpoint met: highly statistically significant and cl...